FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072932261> ?p ?o ?g. }

• W2072932261 endingPage "944" @default.
• W2072932261 startingPage "935" @default.
• W2072932261 abstract "BACKGROUND. Primary systemic therapy (PST) is the standard approach to the management of patients with locally advanced breast cancer (LABC). The authors hypothesized that the intratumoral administration of a nonreplicating adenoviral vector (Ad5) that contains the human wild-type p53, AdCMV-p53, combined with chemotherapy, could increase the efficacy of PST as measured by pathologic complete response. METHODS. In a prospective, open-label, Phase II trial, 13 patients with LABC were treated with 6 3-week cycles of PST, which consisted of intratumoral injections of Ad5CMV-p53 for 2 consecutive days plus docetaxel and doxorubicin followed by surgery. p53 status was determined at baseline and was assessed immediately after the first injection (up to 48 hours). Clinical response was assessed by clinical and radiologic methods. RESULTS. The trial was terminated early, because none of the patients achieved a pathologic complete response. The median age was 56 years (range, 39–71 years), and the median tumor size was 8 cm (range, 5–11 cm). Eight patients (73%) had a p53 mutation. Serial biopsies showed an increase in p53 messenger RNA (mRNA) and p21WAF1/Cip1 mRNA. All 12 evaluable patients achieved an objective clinical response. The surgical specimens revealed scattered tumor cells with extensive tumor-infiltrate leukocytes (predominantly T-lymphocytes). At a median follow-up of 37 months (range, 30–41 months), 4 patients (30%) developed systemic recurrence, and 2 patients died. The estimate breast cancer-specific survival rate at 3 years was 84% (95% confidence interval, 65.7–100%). There was no increase in systemic toxicity. CONCLUSIONS. Ad5CMV-p53 combined with PST is safe, active, and associated with local immunomodulatory effects. The promising clinical activity of this combination deserves further investigation in randomized studies. Cancer 2006. © 2006 American Cancer Society." @default.
• W2072932261 created "2016-06-24" @default.
• W2072932261 creator A5011623863 @default.
• W2072932261 creator A5013487780 @default.
• W2072932261 creator A5015127974 @default.
• W2072932261 creator A5018617106 @default.
• W2072932261 creator A5026926354 @default.
• W2072932261 creator A5027464426 @default.
• W2072932261 creator A5032987754 @default.
• W2072932261 creator A5049108063 @default.
• W2072932261 creator A5068491553 @default.
• W2072932261 creator A5080832682 @default.
• W2072932261 date "2006-01-01" @default.
• W2072932261 modified "2023-10-16" @default.
• W2072932261 title "A nonreplicating adenoviral vector that contains the wild-typep53 transgene combined with chemotherapy for primary breast cancer" @default.
• W2072932261 cites W1616824889 @default.
• W2072932261 cites W190417444 @default.
• W2072932261 cites W1950719160 @default.
• W2072932261 cites W1971558253 @default.
• W2072932261 cites W1971753589 @default.
• W2072932261 cites W1977686001 @default.
• W2072932261 cites W1978224665 @default.
• W2072932261 cites W1987783969 @default.
• W2072932261 cites W2000963309 @default.
• W2072932261 cites W2009722064 @default.
• W2072932261 cites W2021875656 @default.
• W2072932261 cites W2024081693 @default.
• W2072932261 cites W2042712894 @default.
• W2072932261 cites W2048303863 @default.
• W2072932261 cites W2052193554 @default.
• W2072932261 cites W2063335267 @default.
• W2072932261 cites W2076718204 @default.
• W2072932261 cites W2078109925 @default.
• W2072932261 cites W2078512357 @default.
• W2072932261 cites W2128822091 @default.
• W2072932261 cites W2133764807 @default.
• W2072932261 cites W2134915449 @default.
• W2072932261 cites W2153172903 @default.
• W2072932261 cites W2156829792 @default.
• W2072932261 cites W2167910093 @default.
• W2072932261 cites W2322606593 @default.
• W2072932261 cites W2940193671 @default.
• W2072932261 cites W4230527064 @default.
• W2072932261 doi "https://doi.org/10.1002/cncr.22080" @default.
• W2072932261 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16874816" @default.
• W2072932261 hasPublicationYear "2006" @default.
• W2072932261 type Work @default.
• W2072932261 sameAs 2072932261 @default.
• W2072932261 citedByCount "43" @default.
• W2072932261 countsByYear W20729322612012 @default.
• W2072932261 countsByYear W20729322612013 @default.
• W2072932261 countsByYear W20729322612014 @default.
• W2072932261 countsByYear W20729322612015 @default.
• W2072932261 countsByYear W20729322612016 @default.
• W2072932261 countsByYear W20729322612017 @default.
• W2072932261 countsByYear W20729322612020 @default.
• W2072932261 countsByYear W20729322612023 @default.
• W2072932261 crossrefType "journal-article" @default.
• W2072932261 hasAuthorship W2072932261A5011623863 @default.
• W2072932261 hasAuthorship W2072932261A5013487780 @default.
• W2072932261 hasAuthorship W2072932261A5015127974 @default.
• W2072932261 hasAuthorship W2072932261A5018617106 @default.
• W2072932261 hasAuthorship W2072932261A5026926354 @default.
• W2072932261 hasAuthorship W2072932261A5027464426 @default.
• W2072932261 hasAuthorship W2072932261A5032987754 @default.
• W2072932261 hasAuthorship W2072932261A5049108063 @default.
• W2072932261 hasAuthorship W2072932261A5068491553 @default.
• W2072932261 hasAuthorship W2072932261A5080832682 @default.
• W2072932261 hasBestOaLocation W20729322611 @default.
• W2072932261 hasConcept C121608353 @default.
• W2072932261 hasConcept C126322002 @default.
• W2072932261 hasConcept C126894567 @default.
• W2072932261 hasConcept C141071460 @default.
• W2072932261 hasConcept C143998085 @default.
• W2072932261 hasConcept C2776694085 @default.
• W2072932261 hasConcept C2776755627 @default.
• W2072932261 hasConcept C2781190966 @default.
• W2072932261 hasConcept C2781303535 @default.
• W2072932261 hasConcept C31760486 @default.
• W2072932261 hasConcept C530470458 @default.
• W2072932261 hasConcept C71924100 @default.
• W2072932261 hasConcept C90924648 @default.
• W2072932261 hasConceptScore W2072932261C121608353 @default.
• W2072932261 hasConceptScore W2072932261C126322002 @default.
• W2072932261 hasConceptScore W2072932261C126894567 @default.
• W2072932261 hasConceptScore W2072932261C141071460 @default.
• W2072932261 hasConceptScore W2072932261C143998085 @default.
• W2072932261 hasConceptScore W2072932261C2776694085 @default.
• W2072932261 hasConceptScore W2072932261C2776755627 @default.
• W2072932261 hasConceptScore W2072932261C2781190966 @default.
• W2072932261 hasConceptScore W2072932261C2781303535 @default.
• W2072932261 hasConceptScore W2072932261C31760486 @default.
• W2072932261 hasConceptScore W2072932261C530470458 @default.
• W2072932261 hasConceptScore W2072932261C71924100 @default.
• W2072932261 hasConceptScore W2072932261C90924648 @default.
• W2072932261 hasIssue "5" @default.
• W2072932261 hasLocation W20729322611 @default.
• W2072932261 hasLocation W20729322612 @default.

• next